Beta-blockade intolerance in anthracycline-induced cardiomyopathy

Area of Science:

• Cardiology
• Oncology

Background:

• Anthracycline-induced cardiomyopathy (AIC) presents unique hemodynamic and histologic features, including mild ventricular dilatation and restrictive patterns.
• The efficacy and safety of beta-blockade therapy in AIC are not well-established.
• Standard left ventricular adaptation mechanisms may be impaired in AIC, potentially affecting beta-blocker response.

Observation:

• A case study of a patient with AIC is presented.
• Initial beta-blocker administration resulted in global cardiac failure.
• A subsequent attempt after patient stabilization also precipitated cardiac failure.

Findings:

• Beta-blockade initiation may precipitate decompensated heart failure in AIC.
• The restrictive pattern and myocardial fibrosis in AIC might contraindicate standard beta-blocker therapy.
• Recurrent cardiac failure occurred upon re-challenge with beta-blockers.

Implications:

• The safety of beta-blockade in restrictive cardiomyopathies, particularly AIC, requires careful consideration.
• Clinicians should exercise caution when initiating beta-blockers in AIC patients.
• Further research is needed to determine optimal management strategies for heart failure in AIC.